England's cancer drug fund extended for two years
This article was originally published in SRA
England's cancer drugs fund is set to live on for another two years beyond the date it was supposed to be superseded by a new pricing set up1. Manufacturers of oncology drugs will likely welcome another two years of greater stability while uncertainty over the UK's pricing landscape continues.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.